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RAPAMYCIN PREVENTS GVHD IN MOUSE MODEL THROUGH NOVEL
MECHANISM: INCREASE IN REGULATORY T CELLS
Palmer, J.M., Chen, B.J., DeOliviera, D., Le, N., Chao, N.J. Duke
University, Durham, NC.
Rapamycin (RAPA) is an immunosuppressant that has been used
formany years for prevention of rejection in solid organ transplanta-
tion. It also appears to have some impact on acute graft versus host
disease (GVHD) after allogeneic hematopoietic stem cell transplan-
tation (HSCT). In previous experiments done in our lab, RAPA sig-
nificantly improves survival inGVHDmousemodel. Recently, it has
been found that RAPA can increase numbers or enhance survival of
regulatory T cells. In this experiment we further investigate the
mechanisms behind RAPA in amurineGVHDmodel. In several ex-
periments, B10.D2 bonemarrow and splenocytes were injected into
Balb/cmice.Themice had samples of peripheral blood and ear biop-
sies evaluated at two, four and six weeks post-transplantation. Regu-
latoryT cells were analyzed based on intracellular FoxP3 expression
via FACS or immunohistochemistry. At all three time points in the
peripheral blood, the percent of regulatory T cells in total CD41
cellswasnot significantlydifferent.Ondays14 and28 therewere sig-
nificant differences seen in the ear biopsies, both inmorphologic ap-
pearance and percent FoxP3 positive cells of mononuclear cells. On
day 14 there wasmore inflammation in the control arm compared to
the RAPA treatedmice, however, there was a cellular infiltrate pres-
ent in both. The percentage of FoxP3 positive cells was 13% in the
treated arm as compared to 2.5% in the control arm (p 5 0.02).
On day 28, there was a decrease in cellularity in the control arm as
compared to the RAPA arm, however in the RAPA arm there was
a significant increase in percent of FoxP3 positive cells as compared
to control arm: 9%vs 1.2% (p5 0.04).These results suggest that the
mechanism through which RAPA prevents GVHD in this model is
not only immunosuppression but also through the effects of regula-
tory T cells. It appears that the effect is mediated locally in the tis-
sues, rather than through circulating regulatory T cells.343
INITIAL THERAPY FOR ACUTE GRAFT-VERSUS-HOST DISEASE WITH
‘‘LOW-DOSE’’ PREDNISONE (1 mg/kg/day) INSTEAD OF ‘‘STANDARD-
DOSE’’ PREDNISONE (2 mg/kg/day) DOES NOT COMPROMISE MAJOR
OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTA-
TION
Mielcarek, M., Storer, B., Martin, P.J. Fred Hutchinson Cancer Re-
search Center, Seattle, WA.
The optimal glucocorticoid dose for initial treatment of acute
graft-versus-host disease (GVHD) remains to be defined. We hy-
pothesized that initial treatment with ‘‘low-dose’’ glucocortocoids
(equivalent to prednisone, 1 mg/kg/day) would not compromise
major transplantation outcomes compared to treatment with ‘‘stan-
dard-dose’’ glucocorticoids (equivalent to prednisone, 2 mg/kg/
day). In a retrospective review, we identified 347 patients with acute
GVHD who were treated initially with low-dose glucocorticoids
and 386 who were treated at standard doses. All patients were at
least 18 years of age and had transplants between 2000 and 2005
at a single institution. Fifty-eight (17%) of the 347 patients in the
low-dose group subsequently received standard-dose treatment af-
ter inadequate response to low-dose treatment. The mean cumula-
tive prednisone-equivalent doses across time in the low-dose group
were reduced by approximately 48% compared to the standard-dose
group. After adjusting for donor type (unrelated vs other), HLA-
mismatch (any vs other), patient age (continuous), conditioning
intensity (myeloablative vs nonmyeloablative), donor/recipient
gender disparity, prophylactic use of ursodeoxycholic acid and
tacrolimus, GVHD grade at onset of therapy and use of beclome-
thasone dipropionate (time-dependent covariate) in multivariate
analysis, we found no statistically significant differences in out-
comes in the low-dose group compared to the standard-dose group:
overall mortality (hazard ratio [HR], 0.99; 95% confidence interval
[CI], 0.8–1.3), relapse (HR, 1.14; 95% CI, 0.8–1.6), non-relapse
mortality (HR, 0.92; 95% CI, 0.7–1.3). Although the proportion
of patients receiving secondary therapy (including an increasefrom low dose to standard dose) was similar in the two groups,
the onset of secondary therapy occurred sooner in the low-dose
group (HR, 1.94; 95% CI, 1.3–2.8). Endpoints of prednisone-re-
lated morbidity were not assessed in this study. Results were similar
in subgroups of patients with GVHD characterized by rash involv-
ing#50%body surface area and stool volumes#1.0 Lwith or with-
out anorexia, nausea and vomiting (n5 425) and in those with more
severe GVHD (n 5 308). We conclude that, despite a nearly 50%
reduction in the cumulative glucocorticoid dose across time, initial
glucocorticoid treatment at a prednisone-equivalent dose of 1 mg/
kg/day was not associated with inferior outcomes when compared
to initial treatment with standard-dose glucocorticoids.344
OFF-THE-SHELF TUMOR IMMUNOTHERAPY WITH GENETICALLY EN-
HANCED ALLOGENEIC T-CELL PRECURSORS
Zakrzewski, J.L.1, Suh, D.1, Markley, J.C.2, Smith, O.M.1, King, C.1,
Goldberg, G.1, Jenq, R.1, Holland, A.M.1, Grubin, J.1, Cabrera-
Perez, J.1, Lu, S.X.1, Rizzuto, G.1, Sant’Angelo, D.B.1, Riviere, I.2,
Sadelain, M.2, Zuniga-Pflucker, J.C.3, van den Brink, M.R.M.1. 1 Me-
morial Sloan Kettering Cancer Center, New York, NY; 2 Memorial Sloan
Kettering Cancer Center, New York, NY; 3 University of Toronto, Tor-
onto, ON, Canada.
T cell deficiencies can occur in many physiological and patho-
physiological settings such as aging, malignant diseases, and cyto-
static therapy. We recently reported that co-transplantation of in
vitro generated T cell precursors significantly enhances T cell re-
constitution after allogeneicHSCT resulting in increased graft-ver-
sus-tumor activity without graft-versus-host disease. The aim of our
present study was to evaluate if allogeneic T cell precursors can
safely be transferred across MHC barriers in the absence of alloge-
neic HSCs to improve anti-tumor activity in immunosuppressed re-
cipients. We found that adoptively transferred allogeneic (C57BL/
6) precursor cells in irradiated hosts (BALB/c) develop into fully
functional allogeneic T cells characterized by a host-MHC re-
stricted and host-tolerant T cell receptor. We show that adoptively
transferred allogeneic T cell precursors significantly improve sur-
vival of BALB/c mice after irradiation (675 cGy) and enhance
anti-tumor activity against A20 lymphoma and renal cell carcinoma
in syngeneic HSCT recipients. Furthermore, we demonstrate the
feasibility of genetic engineering of antigen-specific T cell precur-
sors, by transducing them to express a chimeric antigen receptor
(CAR) targeting hCD19. Immunotherapy with CAR-expressing T
cell precursors resulted in the in vivo generation of high numbers
of appropriately selected T cells expressing the CAR, which
persisted for at least two months after transfer and mediated signif-
icantly enhanced anti-tumor activity (compared with CAR-negative
T cell precursors) against a CAR-sensitive tumor, without any un-
desirable auto/alloreactivity. We conclude that T cell precursors
from any donor can be used universally for adoptive immunother-
apy in any immunosuppressed individual irrespective of MHC dis-
parities. The use of allogeneic precursors cells instead of autologous
cells eliminates the risk of contamination with residual malignant
patient cells and allows the generation and storage of virtually un-
limited quantities of precursor cells for ‘off-the-shelf’ immunother-
apy. This procedure is not only labor and cost-effective, but it
facilitates the application of gene transfer technology, to generate
antigen-specific or otherwise enhanced designer cells. Adoptive
transfer of allogeneic and genetically enhanced T cell precursors
therefore represents a promising novel strategy for targeted ‘off-
the-shelf’ immunotherapy in immunosuppressed patients.345
DECREASED RISK OF ACUTE GVHD FOLLOWING ALLOGENEIC HEMATO-
POIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH THE 5,10-
METHYLENETETRAHYDROFOLATE REDUCTASE 677TT GENOTYPE
Sugimoto, K.1, Murata, M.1, Onizuka, M.2, Inamoto, Y.2,
Terakura, S.1, Kuwatsuka, Y.2, Oba, T.2, Miyamura, K.2, Kodera, Y.2,
Naoe, T.1. 1 Nagoya University Graduate School of Medicine, Nagoya,
Aichi, Japan; 2 Japanese Red Cross Nagoya First Hospital, Nagoya, Aichi,
Japan.
